According to GuruFocus' list of 52-week highs, these guru stocks have reached their 52-week highs.
Laboratory Corp. of America Holdings reaches 52-week high of $126.61
Through its national network of laboratories, Laboratory Corp. of America Holdings (LH, Financial) offers a broad range of clinical laboratory tests that are used by the medical profession in routine testing, patient diagnosis and in the monitoring and treatment of disease. In addition, the company has developed testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials.
Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens.
The price of Laboratory Corp. of America Holdings shares has reached $126.61, which is 1.8% off the 52-week high of $128.84. Laboratory Corp. of America Holdings has a market cap of $12.96 billion; its shares were traded around $126.61 with a P/E ratio of 21.87 and P/S ratio of 1.40. Laboratory Corp. of America Holdings had an annual average earnings growth of 9.10% over the past 10 years. GuruFocus rated Laboratory Corp. of America Holdings the business predictability rank of 4-star.
The company recently reported net revenue for the first quarter was $2.30 billion, an increase of 29.5% over last year’s $1.77 billion. The Covance acquisition contributed $687.3 million in net revenue during the quarter, compared to $267.2 million in the first quarter of 2015 following the date of closing on Feb. 19, 2015, driving an increase of 23.7% year over year.
EVP, CEO of LabCorp Diagnostics James T. Boyle Jr. sold 18,132 shares of Laboratory Corp. of America Holdings stock on March 31 at the average price of $116.81. Boyle owns at least 23,454 shares. The price of the stock has increased by 8.39%.
Airgas reaches 52-week high of $142.95
Airgas Inc. (ARG, Financial) is a supplier of industrial, medical and specialty gases, and hardgoods, such as welding equipment and related products. The company is a producer of atmospheric gases, carbon dioxide, dry ice and nitrous oxide, suppliers of safety products and a U.S. supplier of refrigerants, ammonia products and process chemicals. Its production network and supply agreements, gas supply modes (from cylinders to truckload quantities to on-site pipeline supply) and national footprint make it one of the few fully integrated industrial gas companies in the U.S. The company also offers supply chain management services and solutions and product and process technical support across many diverse customer segments.
The price of Airgas shares has reached $142.95, which is 0.1% off the 52-week high of $143.05. Airgas has a market cap of $10.41 billion; its shares were traded around $142.95 with a P/E ratio of 31.56 and P/S ratio of 2.01. The trailing 12-month dividend yield of Airgas stocks is 1.68%. The forward dividend yield of Airgas stocks is 1.68%. Airgas had an annual average earnings growth of 10.00% over the past 10 years. GuruFocus rated Airgas the business predictability rank of 5-star.
The company recently reported earnings per diluted share of $1.01, including 18 cents per diluted share of merger costs for its third quarter ended Dec. 31, 2015. Adjusted diluted EPS of $1.19 is down 3% compared to prior-year diluted EPS of $1.23. The company also reported third-quarter sales of $1.3 billion, which has decreased 3% compared to the prior year.
President and CEO Michael Molinini sold 30,000 shares of Airgas stock on Feb. 24 at the average price of $141.32. The price of the stock has increased by 1.15%.
Baxalta reaches 52-week high of $44.43
Baxalta Incorporated (BXLT, Financial) is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology and oncology. The company offers biopharmaceuticals for the treatment of hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency and other similar things.
The price of Baxalta shares has reached $44.43, which is 0.5% off the 52-week high of $44.65. Baxalta has a market cap of $30.37 billion; its shares were traded around $44.43 with a P/E ratio of 36.72 and P/S ratio of 4.78. The trailing 12-month dividend yield of Baxalta stock is 0.47%. The forward dividend yield of Baxalta stock is 0.63%.
The company recently reported that in the first quarter, on a GAAP basis, Baxalta’s worldwide revenues of $1.5 billion advanced 14% from the prior-year period. Excluding the impact of foreign currency, sales advanced 18%. In the first quarter, Baxalta generated net income on a GAAP basis of $145 million and earnings of 21 cents per diluted share. These results include net after-tax special items totaling $181 million, or 26 cents per diluted share.
Director Blake E. Devitt bought 5,900 shares of Baxalta stock on Feb. 25 at the average price of $39.17. The price of the stock has increased by 13.43%.
Fidelity National Information Services reaches 52-week high of $72.98
Fidelity National Information Services Inc. (FIS, Financial) is a provider of banking and payments technologies, complemented by strategic consulting services, professional services and outsourcing services. Through its Capco brand, the company delivers globally a wide range of information technology consulting and transformational services to financial institutions. Its services includes integrated consulting services, integrated core banking and payment solutions, mobile banking solutions, item processing services, card issuer services, risk management solutions, electronic loan amendment applications and services, electronic funds transfer (EFT) services and prepaid/gift card processing for community banks, credit unions and other financial institutions.
The prices of Fidelity National Information Services shares have reached $72.98, which is 1.7% off the 52-week high of $74.19. Fidelity National Information Services has a market cap of $23.82 billion; its shares were traded around $72.98 with a P/E ratio of 36.86 and P/S ratio of 3.00. The trailing 12-month dividend yield of Fidelity National Information Services stock is 1.43%. The forward dividend yield of Fidelity National Information Services stock is 1.43%. Fidelity National Information Services had an annual average earnings growth of 5.60% over the past 10 years.
The company recently reported that first quarter 2016 revenue increased to $2.2 billion from $1.6 billion in the first quarter of 2015. GAAP net earnings from continuing operations attributable to common stockholders was $55 million, or 17 cents per diluted share, compared to $114 million, or 40 cents per diluted share in the prior-year quarter.
President and CEO Gary Norcross sold 170,000 shares of Fidelity National Information Services stock on March 30 at the average price of $63.05. The price of the stock has increased by 15.75% since.
Zimmer Biomet Holdings reaches 52-week high of $119.33
Zimmer Biomet Holdings Inc. (ZBH, Financial) is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, cranio maxillofacial and thoracic products; dental implants and related surgical products. It also provides other health care-related services. Its products include orthopaedic reconstructive implants, spinal and trauma devices, biologics, dental implants and related surgical products.
The price of Zimmer Biomet Holdings shares has reached $119.33, which is 0.6% off the 52-week high of $119.99. Zimmer Biomet Holdings has a market cap of $23.78 billion; its shares were traded around $119.33 with a P/E ratio of 350.97 and P/S ratio of 3.42. The trailing 12-month dividend yield of Zimmer Biomet Holdings stock is 0.75%. The forward dividend yield of Zimmer Biomet Holdings stock is 0.80%. Zimmer Biomet Holdings had an annual average earnings growth of 4.00% over the past 10 years. GuruFocus rated Zimmer Biomet Holdings the business predictability rank of 2.5-star.
The company recently reported net earnings for the first quarter 2016 were $105.9 million on a reported basis and $404.3 million on an adjusted basis, an increase of 51.5% adjusted over the prior-year period.
President and CEO David C. Dvorak sold 1,540 shares of Zimmer Biomet Holdings stock on March 21 at the average price of $104.16. The price of the stock has increased by 14.56% since.
Start a free seven-day trial of Premium Membership to GuruFocus.
